You are here
Inhaled nitric oxide therapy fails to improve outcome in experimental severe influenza.
Title | Inhaled nitric oxide therapy fails to improve outcome in experimental severe influenza. |
Publication Type | Journal Article |
Year of Publication | 2012 |
Authors | Darwish, I, Miller, C, Kain, KC, W Liles, C |
Journal | Int J Med Sci |
Volume | 9 |
Issue | 2 |
Pagination | 157-62 |
Date Published | 2012 |
ISSN | 1449-1907 |
Keywords | Administration, Inhalation, Animals, Cells, Cultured, Disease Models, Animal, Dogs, Drug Evaluation, Preclinical, Female, Influenza A Virus, H1N1 Subtype, Lung, Mice, Mice, Inbred C57BL, Nitric Oxide, Orthomyxoviridae Infections, Severity of Illness Index, Treatment Failure, Viral Load |
Abstract | In vitro, nitric oxide (NO) has been shown to have antimicrobial activity against a wide range of viruses, including influenza A virus. Therefore, we hypothesized that inhaled nitric oxide (iNO) would increase survival in vivo by reducing the viral load in C57Bl/6 mice infected with a lethal dose of influenza A/WSN/33 (H1N1; WSN/33) virus. NO was delivered to influenza-infected mice either continuously or intermittently at 80 or 160 ppm, respectively, using both prophylactic and post-infection treatment strategies. Murine survival and weight loss were assessed, and lung viral load was quantified via plaque assay. Here, we report that iNO administered prophylactically or post-influenza infection failed to improve survival of infected mice. No difference in lung viral load was observed between experimental groups. Although NO has antiviral activity against influenza A virus in vitro, iNO therapy provided no apparent benefit when used for treatment of influenza A virus infection in vivo. |
DOI | 10.7150/ijms.3880 |
Alternate Journal | Int J Med Sci |
PubMed ID | 22253563 |